Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA. Swain SM, et al. Among authors: ewer ms. J Clin Oncol. 1997 Apr;15(4):1318-32. doi: 10.1200/JCO.1997.15.4.1318. J Clin Oncol. 1997. PMID: 9193323 Clinical Trial.
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group. Swain SM, et al. Among authors: ewer ms. Ann Oncol. 2018 Mar 1;29(3):646-653. doi: 10.1093/annonc/mdx773. Ann Oncol. 2018. PMID: 29253081 Free PMC article. Clinical Trial.
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J. Tan-Chiu E, et al. J Clin Oncol. 2005 Nov 1;23(31):7811-9. doi: 10.1200/JCO.2005.02.4091. J Clin Oncol. 2005. PMID: 16258083 Clinical Trial.
Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014).
Ewer M, Gianni L, Pane F, Sandri MT, Steiner RK, Wojnowski L, Yeh ET, Carver JR, Lipshultz SE, Minotti G, Armstrong GT, Cardinale D, Colan SD, Darby SC, Force TL, Kremer LC, Lenihan DJ, Sallan SE, Sawyer DB, Suter TM, Swain SM, van Leeuwen FE. Ewer M, et al. Ecancermedicalscience. 2014 May 29;8:433. doi: 10.3332/ecancer.2014.433. eCollection 2014. Ecancermedicalscience. 2014. PMID: 24932213 Free PMC article.
Reply to K. Anand et al and K. Kunimasa.
Ewer MS. Ewer MS. J Clin Oncol. 2021 Jun 20;39(18):2051-2052. doi: 10.1200/JCO.21.00502. Epub 2021 Apr 23. J Clin Oncol. 2021. PMID: 33891499 No abstract available.
Cardiac Safety of Osimertinib: A Review of Data.
Ewer MS, Tekumalla SH, Walding A, Atuah KN. Ewer MS, et al. J Clin Oncol. 2021 Feb 1;39(4):328-337. doi: 10.1200/JCO.20.01171. Epub 2020 Dec 23. J Clin Oncol. 2021. PMID: 33356419 Free PMC article. Review.
137 results